PeptiDream Inc (4587.T)
3,955JPY
21 Aug 2018
¥145 (+3.81%)
¥3,810
¥3,800
¥3,970
¥3,800
613,100
943,983
¥5,780
¥3,065
Latest Key Developments (Source: Significant Developments)
PeptiDream says completion of technology transfer of Peptide Discovery Platform System to Shionogi
May 17 (Reuters) - PeptiDream Inc <4587.T>:Says co completed the transfer of co's proprietary Peptide Discovery Platform System (PDPS) technology to Shionogi & Co Ltd <<<4507.T>>>.Under the terms of the nonexclusive license agreement entered into by the co and Shionogi in June 2017, co will receive an undisclosed milestone payment and is eligible to receive additional technology access payments, in addition to payments based on achievement of certain predetermined development milestones for any constrained peptides and/or small molecules discovered from use of the PDPS technology.In addition, co is eligible to receive royalties on sales of certain products that arise from use of the PDPS technology . Full Article
PeptiDream to invest 1.8 bln yen in peptide drugs unit
March 30 (Reuters) - PeptiDream Inc <4587.T>:Says it will invest 1.8 billion yen in Osaka-based peptide drugs unit .Says it will hold 17.3 percent stake in Osaka-based unit after investment . Full Article
Peptidream announces discovery collaboration agreement with Bayer
Nov 19 (Reuters) - Peptidream Inc <4587.T>:Peptidream announces discovery collaboration agreement with bayer.Entered into a multi-target discovery collaboration with Germany-based Bayer AG.Under terms , co would receive undisclosed upfront payment and research funding.Under terms, co is eligible to receive preclinical, clinical, commercialization milestone payments totaling up to $1.11 billion.Also eligible to receive royalties on sales of any products that arise from collaboration. Full Article
PeptiDream announces discovery collaboration agreement with Bayer AG
Nov 16 (Reuters) - PeptiDream Inc <4587.T>:Says it announced today that it has entered into a multi-target discovery collaboration with Germany-based Bayer AG.Under the terms of the agreement, it would receive an undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments potentially totaling up to $1.11 billion (124.5 billion yen) .In addition, it is eligible to receive royalties on sales of any products that arise from the collaboration . Full Article
Nikkei rises to 3-1/2-month high on lower yen, marks 8th winning week
TOKYO, May 18 Japan's Nikkei share average rose to a 3-1/2-month high on Friday and scored its eighth straight weekly gain after a weaker yen lifted exporters, while financial stocks extended their rally as U.S. bond yields remained high.
Earnings vs. 
Estimates